BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12222584)

  • 1. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
    Hudson JQ; Sameri RM
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the pharmacokinetic disposition of darbepoetin alfa.
    Zamboni WC; Stewart CE
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):133S-140S. PubMed ID: 12222583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.
    Gobin J; Cernii A; McLean R; Finkelstein FO; Simon DB
    Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.
    Valley AW
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):150S-159S. PubMed ID: 12222585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
    Cases A
    Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa.
    Ibbotson T; Goa KL
    Drugs; 2001; 61(14):2097-104; discussion 2105-6. PubMed ID: 11735636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
    Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R
    Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa: its use in anemia associated with chronic kidney disease.
    Robinson DM; Easthope SE
    BioDrugs; 2005; 19(5):327-43. PubMed ID: 16207074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.